Physician profile
Christopher Odea
NPI 1194112433
$4,223.80
in general payments reported to CMS, 2019-2025
24 companies · $1,960 in 2025
The $1,960 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $430 · 2022: $439 · 2023: $477 · 2024: $919 · 2025: $1,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498 · Travel and Lodging: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,497.69 |
| Travel and Lodging | $858.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $993.61 | 2024-2025 | Corevalve Evolut R, Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $377.46 | 2022-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $376.97 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $353.93 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $285.83 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $257.32 | 2021-2025 | |
| Abbott Laboratories | $204.10 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $194.20 | 2023-2025 | Impella |
| Pfizer INC. | $192.66 | 2022-2025 | |
| Boston Scientific Corporation | $149.00 | 2024 | Watchman Flx |
| Recor Medical INC | $114.56 | 2025 | Paradise Ultrasound Renal Denervation System |
| United Therapeutics Corporation | $107.57 | 2023-2025 | Tyvaso, Tyvaso |
| Novo Nordisk INC | $107.52 | 2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $99.70 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.62 | 2021-2023 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $59.91 | 2022-2024 | Repatha |
| Merck Sharp & Dohme LLC | $56.36 | 2022-2025 | Verquvo |
| Scpharmaceuticals INC. | $50.96 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $45.62 | 2023-2025 | Opsumit, Uptravi |
| Cordis US Corp. | $38.88 | 2024-2025 | Mynx Control Venous, Infiniti |
| Astrazeneca Pharmaceuticals Lp | $29.46 | 2023-2024 | Farxiga |
| Bridgebio Pharma, INC. | $20.85 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $16.71 | 2024 | |
| Alexion Pharmaceuticals, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Odea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.